Biacore International AB -- Delisting of American Depositary Receipts from Nasdaq

Uppsala, SWEDEN


UPPSALA, Sweden, May 14, 2004 (PRIMEZONE) -- Biacore International AB (Biacore) (Stockholmsborsen: BCOR; Nasdaq: BCOR) today announced that it has requested that its American Depositary Receipts under its trading symbol "BCOR" be delisted from the Nasdaq National Market, effective as of May 21, 2004.

This action will not affect the continuing listing of Biacore's shares on Stockholmsborsen.

Biacore's shares were registered with the SEC and listed on Nasdaq National Market in 1996 in the form of ADRs, each representing one ordinary share. At such time as the ADRs are delisted from Nasdaq National Market, registered holders will be contacted by the Company's Depositary Bank in respect of the ADRs, JP Morgan, with instructions regarding how to proceed.

For further information, please contact:

Lars-Olov Forslund,CFO +41(0)79 347 9900 Jan Isoz, Investor Relations +46 70 81 03 117

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) technology based systems with its own sales operations in the U.S., across Europe, Japan, Australia and New Zealand. A strong patent portfolio protects Biacore's SPR technology, which gives unique real-time insights into biomolecular interactions. Target groups for the Company's products consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies around the world. Biacore is focusing on drug discovery and development as its prime areas for future growth. The Company currently has seven systems on the market, the most important of which are: Biacore(R)S51 for applications downstream of high-throughput screening (HTS) including rapid characterization of HTS hits and comprehensive pre-clinical evaluation of lead compounds, Biacore(R)3000, which offers flexibility in key life science research and drug discovery applications upstream of HTS, and Biacore(R)C which is specifically designed for compliant concentration analysis of biopharmaceuticals in GLP/GMP applications. A new SPR array system, which will provide higher information content, is expected to reach the market in 2004.

Based in Uppsala, Sweden, the Company is listed on Stockholmsborsen and Nasdaq in the U.S. In 2003 the Company had sales of SEK 515.5 million and an operating income of SEK 29.5 million.

Further information on Biacore can be found on the web: www.biacore.com

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

http://www.waymaker.net/bitonline/2004/05/14/20040514BIT00340/wkr0001.doc

http://www.waymaker.net/bitonline/2004/05/14/20040514BIT00340/wkr0002.pdf